Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 12/2007

01-12-2007 | Original Article

Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer

Authors: Lisa H. Butterfield, Antoni Ribas, Douglas M. Potter, James S. Economou

Published in: Cancer Immunology, Immunotherapy | Issue 12/2007

Login to get access

Abstract

We are investigating the use of Alpha Fetoprotein (AFP) as a tumor rejection antigen for hepatocellular carcinoma (HCC). We recently completed vaccination of 10 AFP+/HLA-A2.1+ HCC subjects with AFP peptide-pulsed autologous dendritic cells (DC). There were increased frequencies of circulating AFP-specific T cells and of IFNγ-producing AFP-specific T cells after vaccination. In order to better understand the lack of association between immune response and clinical response, we have examined additional aspects of the AFP immune response in patients. Here, we have characterized the cell surface phenotype of circulating AFP tetramer-positive CD8 T cells and assessed AFP-specific CD4 function. Before vaccination, HCC subjects had increased frequencies of circulating AFP-specific CD8 T cells with a range of naïve, effector, central and effector memory phenotypes. Several patients had up-regulated activation markers. A subset of patients was assessed for phenotypic changes pre- and post-vaccination, and evidence for complete differentiation to effector or memory phenotype was lacking. CD8 phenotypic and cytokine responses did not correlate with level of patient serum AFP antigen (between 74 and 463,040 ng/ml). Assessment of CD4+ T cell responses by ELISPOT and multi-cytokine assay did not identify any spontaneous CD4 T cell responses to this secreted protein. These data indicate that there is an expanded pool of partially differentiated AFP-specific CD8 T cells in many of these HCC subjects, but that these cells are largely non-functional, and that a detectable CD4 T cell response to this secreted oncofetal antigen is lacking.
Literature
1.
go back to reference Butterfield LH et al (2003) T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res 9(16 Pt 1):5902–5908PubMed Butterfield LH et al (2003) T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res 9(16 Pt 1):5902–5908PubMed
2.
go back to reference Butterfield LH et al (2006) A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 12(9):2817–2825PubMedCrossRef Butterfield LH et al (2006) A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 12(9):2817–2825PubMedCrossRef
3.
4.
go back to reference Alisa A et al (2005) Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients. Clin Cancer Res 11(18):6686–6694PubMedCrossRef Alisa A et al (2005) Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients. Clin Cancer Res 11(18):6686–6694PubMedCrossRef
5.
go back to reference Butterfield LH et al (1999) Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res 59(13):3134–3142PubMed Butterfield LH et al (1999) Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res 59(13):3134–3142PubMed
6.
go back to reference Butterfield LH et al (2001) T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol 166(8):5300–5308PubMed Butterfield LH et al (2001) T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol 166(8):5300–5308PubMed
7.
go back to reference Hanke P et al (2002) Cirrhotic patients with or without hepatocellular carcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human alpha-fetoprotein. Scand J Gastroenterol 37(8):949–955PubMedCrossRef Hanke P et al (2002) Cirrhotic patients with or without hepatocellular carcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human alpha-fetoprotein. Scand J Gastroenterol 37(8):949–955PubMedCrossRef
8.
go back to reference Liu Y et al (2006) Hierarchy of AFP-specific T cell responses in subjects with AFP-positive hepatocellular cancer. J Immunol 177(1):712–721PubMed Liu Y et al (2006) Hierarchy of AFP-specific T cell responses in subjects with AFP-positive hepatocellular cancer. J Immunol 177(1):712–721PubMed
9.
go back to reference Hamann D et al (1997) Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 186(9):1407–1418PubMedCrossRef Hamann D et al (1997) Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 186(9):1407–1418PubMedCrossRef
10.
go back to reference Sallusto F, Geginat J, Lanzavecchia A (2004), Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22:745–763PubMedCrossRef Sallusto F, Geginat J, Lanzavecchia A (2004), Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22:745–763PubMedCrossRef
11.
go back to reference Sallusto F et al (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401(6754):708–712PubMedCrossRef Sallusto F et al (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401(6754):708–712PubMedCrossRef
12.
go back to reference Lee PP (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5(6):677–685PubMedCrossRef Lee PP (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5(6):677–685PubMedCrossRef
13.
go back to reference Dunbar PR et al (2000) A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol 165(11):6644–6652PubMed Dunbar PR et al (2000) A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol 165(11):6644–6652PubMed
14.
go back to reference Pittet MJ et al (1999) High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 190(5):705–715PubMedCrossRef Pittet MJ et al (1999) High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 190(5):705–715PubMedCrossRef
15.
go back to reference Speiser DE, Cerottini JC, Romero P (2002) Can hTERT peptide (540–548)-specific CD8 T cells recognize and kill tumor cells? Cancer Immun 2:14PubMed Speiser DE, Cerottini JC, Romero P (2002) Can hTERT peptide (540–548)-specific CD8 T cells recognize and kill tumor cells? Cancer Immun 2:14PubMed
16.
go back to reference Pittet MJ et al (2001) Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin Cancer Res 7(3 Suppl):796s–803sPubMed Pittet MJ et al (2001) Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin Cancer Res 7(3 Suppl):796s–803sPubMed
17.
go back to reference Kim JW et al (2004) Expression of pro- and antiapoptotic proteins in circulating CD8+ T cells of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 10(15):5101–5110PubMedCrossRef Kim JW et al (2004) Expression of pro- and antiapoptotic proteins in circulating CD8+ T cells of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 10(15):5101–5110PubMedCrossRef
18.
go back to reference Kim JW, Ferris RL, Whiteside TL (2005) Chemokine C receptor 7 expression and protection of circulating CD8+ T lymphocytes from apoptosis. Clin Cancer Res 11(21):7901–7910PubMedCrossRef Kim JW, Ferris RL, Whiteside TL (2005) Chemokine C receptor 7 expression and protection of circulating CD8+ T lymphocytes from apoptosis. Clin Cancer Res 11(21):7901–7910PubMedCrossRef
19.
go back to reference Meng WS et al (2001) alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 61(24):8782–8786PubMed Meng WS et al (2001) alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 61(24):8782–8786PubMed
20.
go back to reference Herr W et al (1996) Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Meth 191(2):131–142CrossRef Herr W et al (1996) Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Meth 191(2):131–142CrossRef
21.
go back to reference Mayer S et al (1996) A sensitive proliferation assay to determine the specific T cell response against HLA-A2.1-binding peptides. J Immunol Meth 197(1–2):131–137CrossRef Mayer S et al (1996) A sensitive proliferation assay to determine the specific T cell response against HLA-A2.1-binding peptides. J Immunol Meth 197(1–2):131–137CrossRef
22.
go back to reference Huang J et al (2005) Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 28(3):258–267PubMedCrossRef Huang J et al (2005) Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 28(3):258–267PubMedCrossRef
23.
go back to reference Appay V et al (2002) Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8(4):379–385PubMedCrossRef Appay V et al (2002) Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8(4):379–385PubMedCrossRef
24.
go back to reference Smith CL et al (2005) Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J Immunol 175(12):8431–8437PubMed Smith CL et al (2005) Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J Immunol 175(12):8431–8437PubMed
25.
go back to reference Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy–a practical partnership. Nat Rev Cancer 5(5):397–405PubMedCrossRef Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy–a practical partnership. Nat Rev Cancer 5(5):397–405PubMedCrossRef
26.
go back to reference Ajuebor MN, Carey JA, Swain MG (2006) CCR5 in T cell-mediated liver diseases: what’s going on? J Immunol 177(4):2039–2045PubMed Ajuebor MN, Carey JA, Swain MG (2006) CCR5 in T cell-mediated liver diseases: what’s going on? J Immunol 177(4):2039–2045PubMed
27.
go back to reference Tatsumi T et al (2003) Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 63(15):4481–4489PubMed Tatsumi T et al (2003) Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 63(15):4481–4489PubMed
28.
go back to reference Butterfield LH et al (2003) Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9(3):998–1008PubMed Butterfield LH et al (2003) Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9(3):998–1008PubMed
29.
go back to reference Ribas A et al (2004) Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 27(5):354–367PubMedCrossRef Ribas A et al (2004) Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 27(5):354–367PubMedCrossRef
30.
go back to reference Evdokimova VN et al (2007) AFP specific CD4+ helper T cell responses in healthy donors and HCC patients. J Immunother (in press) Evdokimova VN et al (2007) AFP specific CD4+ helper T cell responses in healthy donors and HCC patients. J Immunother (in press)
31.
go back to reference Seregni E, Botti C, Bombardieri E (1995) Biochemical characteristics and clinical applications of alpha-fetoprotein isoforms. Anticancer Res 15(4):1491–1499PubMed Seregni E, Botti C, Bombardieri E (1995) Biochemical characteristics and clinical applications of alpha-fetoprotein isoforms. Anticancer Res 15(4):1491–1499PubMed
32.
go back to reference Heydtmann M et al (2006) Detailed analysis of intrahepatic CD8 T cells in the normal and hepatitis C-infected liver reveals differences in specific populations of memory cells with distinct homing phenotypes. J Immunol 177(1):729–738PubMed Heydtmann M et al (2006) Detailed analysis of intrahepatic CD8 T cells in the normal and hepatitis C-infected liver reveals differences in specific populations of memory cells with distinct homing phenotypes. J Immunol 177(1):729–738PubMed
33.
go back to reference Dumortier H et al (2005) Antigen presentation by an immature myeloid dendritic cell line does not cause CTL deletion in vivo, but generates CD8+ central memory-like T cells that can be rescued for full effector function. J Immunol 175(2):855–863PubMed Dumortier H et al (2005) Antigen presentation by an immature myeloid dendritic cell line does not cause CTL deletion in vivo, but generates CD8+ central memory-like T cells that can be rescued for full effector function. J Immunol 175(2):855–863PubMed
34.
go back to reference Speiser DE et al (2002) In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur J Immunol 32(3):731–741PubMedCrossRef Speiser DE et al (2002) In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur J Immunol 32(3):731–741PubMedCrossRef
35.
go back to reference Harari A et al (2005) Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol 174(2):1037–1045PubMed Harari A et al (2005) Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol 174(2):1037–1045PubMed
36.
go back to reference Beckebaum S, et al (2002) Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol 104(2):138–150PubMedCrossRef Beckebaum S, et al (2002) Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol 104(2):138–150PubMedCrossRef
37.
go back to reference Ninomiya T et al (1999) Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol 31(2):323–331PubMedCrossRef Ninomiya T et al (1999) Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol 31(2):323–331PubMedCrossRef
38.
go back to reference Piccioli D et al (2005) Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol 42(1):61–67PubMedCrossRef Piccioli D et al (2005) Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol 42(1):61–67PubMedCrossRef
39.
go back to reference Bei R et al (1999) Cryptic epitopes on alpha-fetoprotein induce spontaneous immune responses in hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis patients. Cancer Res 59(21):5471–5474PubMed Bei R et al (1999) Cryptic epitopes on alpha-fetoprotein induce spontaneous immune responses in hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis patients. Cancer Res 59(21):5471–5474PubMed
40.
go back to reference Curtsinger JM, (2005) Signal 3 tolerant CD8 T cells degranulate in response to antigen but lack granzyme B to mediate cytolysis. J Immunol 175(7):4392–4399PubMed Curtsinger JM, (2005) Signal 3 tolerant CD8 T cells degranulate in response to antigen but lack granzyme B to mediate cytolysis. J Immunol 175(7):4392–4399PubMed
41.
go back to reference Curtsinger JM et al (2005) Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 174(8):4465–4469PubMed Curtsinger JM et al (2005) Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 174(8):4465–4469PubMed
42.
go back to reference Schumacher L et al (2004) Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother 27(3):191–200PubMedCrossRef Schumacher L et al (2004) Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother 27(3):191–200PubMedCrossRef
Metadata
Title
Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer
Authors
Lisa H. Butterfield
Antoni Ribas
Douglas M. Potter
James S. Economou
Publication date
01-12-2007
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 12/2007
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-007-0337-9

Other articles of this Issue 12/2007

Cancer Immunology, Immunotherapy 12/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine